Navigation Links
Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
Date:8/4/2010

QUÉBEC CITY, Aug. 4 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, will announce its second quarter 2010 financial and operating results before market open on Thursday, August 12, 2010. The Company will host a conference call and webcast to discuss these results later that same day at 1:30 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: in Canada, 514-807-9895 or 647-427-7451, outside Canada, 888-231-8191. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
2. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
3. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
4. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
5. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
6. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
7. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
8. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
9. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
10. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
11. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... CNA Finance ... had provided a research update on Aytu Bioscience and cited promising increases in ... to Soulstring, prescription rates for Natesto® have more than doubled since March of ...
(Date:8/16/2017)... ... August 16, 2017 , ... Tunnell Consulting announced today ... the ISPE Annual Meeting and Expo , to be held October 29 through ... theme is “Driving innovation to advance patient therapies.” , The ISPE Annual Meeting and ...
(Date:8/16/2017)... ... August 16, 2017 , ... Recent studies show that ... treatments for specific cancers, such as breast, prostate, or lung, target vital pathways ... therapy for advanced prostate cancer. , This therapy limits the production and ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, ... it has secured $2M in funding from an impressive group of investors, including ... SVG Thrive Fund. With this investment, 3Bar is broadening availability of its groundbreaking ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):